Bone Marrow Transplantation

Mycophenolate Mofetil Can Prevent Acute Graft-Versus-Host Disease in HLA-Mismatched Recipients

Published in Blood Weekly, May 18th, 2000

Researchers writing in Clinical Transplantation report that mycophenolate mofetil (MMF), in combination with other immunosuppressive drugs, can prevent acute graft-versus-host disease (aGVHD) in bone marrow and peripheral blood stem cell transplant patients.

N. Basara and colleagues in Germany studied the effectiveness of prophylactic MMF, already shown to be effective for kidney and heart transplant recipients, on 13 patients receiving transplants from human leukocyte antigen (HLA)-mismatched donors, according to their report ("Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients," Clin Transplant,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry